Search

everythinglearnresearchcommunity

for

Search:↓

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Users find ChatGPT a helpful tool for researching these treatments.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

Stress can increase androgen sensitivity, potentially worsening hair loss. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user experienced significant hair regrowth using a regimen of 1 mg finasteride daily, minoxidil twice daily, ketoconazole shampoo weekly, dermastamping weekly, and tretinoin. They reported no side effects and emphasized the importance of committing to the treatment.

A user reported no success with Minoxidil after a year but observed good regrowth after taking 5000 IU of vitamin D3 daily for 2.5 months. They are seeking opinions on whether they will see full regrowth and if others have had similar experiences.

The user has been treating hair loss for over 11 years with various methods including Minoxidil, Keto shampoos, vitamins, and microneedling, but has avoided Finasteride due to fertility concerns. They have recently added Zix and The Ordinary Serum to their routine and are questioning their high DHT levels despite their efforts.

A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.